Effects of Budesonide and Fluticasone Propionate in Pediatric Asthma Patients
Article Outline
Background
Cytokines and chemokines play important roles in asthma. However, little information exists on the effects of inhaled corticosteroids on cytokine and chemokine plasma levels in childhood asthma. We compared the pharmaceutical effects of two inhaled corticosteroids used in pediatric patients with mild-to-moderate asthma, budesonide and fluticasone propionate.
Methods
Pediatric patients aged 5–18 years old were enrolled in this randomized, open-label, observer-blinded study and received 3 months of treatment with either inhaled budesonide (200 mg/puff) or fluticasone propionate (250 mg/puff), at two puffs per day. Peak expiratory flow (PEF), exhaled nitric oxide, Asthma Control Test (ACT), plasma levels of tumor necrosis factor-a, thymus and activation-regulated chemokine, and interferon-inducible protein 10 were measured before treatment and monthly for 3 months after treatment.
Results
There were six patients in the budesonide group, and eight in the fluticasone group. After 3 months, both groups showed improved PEF. In the first month, PEF improved more in the budesonide group than in the fluticasone group, though the difference was not significant. After treatment, ACT scores in both groups were well controlled, except for one patient in the fluticasone group. The fluticasone group had a more significant reduction in exhaled nitric oxide than the budesonide group in the first month.
Conclusion
Improvements in lung function were more rapid in the budesonide group than the fluticasone group. However, patients in the fluticasone group had better anti-inflammatory responses than those in the budesonide group. We conclude that each inhaled corticosteroids have its own clinical and laboratory effects.
Key Words: asthma , budesonide , chemokine , cytokine , exhaled NO , fluticasone
No full text is available. To read the body of this article, please view the PDF online.
References
- . Inflammatory mediators of asthma: an update . Pharmacol Rev . 1998;50:515–596
- . Tumour necrosis factor-alpha: the role of this multifunctional cytokine in asthma . Immunol Cell Biol . 2001;79:132–140
- . Cytokines in asthma . Eur Respir J Suppl . 2001;34:24s–33s
- . Release of both CCR4-active and CXCR3-active chemokines during human allergic pulmonary late-phase reactions . J Allergy Clin Immunol . 2003;112:930–934
- . Enhanced generation of helper T type 1 and 2 chemokines in allergen-induced asthma . Am J Respir Crit Care Med . 2004;169:1118–1124
- . Discrepant clinical responses and blood chemokine profiles between two non-steroidal anti-inflammatory medications for children with mild persistent asthma . Pediatr Allergy Immunol . 2005;16:306–309
- Plasma TARC concentration may be a useful marker for asthmatic exacerbation in children . Eur Respir J . 2003;21:616–620
- . The T cell-directed CC chemokine TARC is a highly specific biological ligand for CC chemokine receptor 4 . J Biol Chem . 1997;272:15036–15042
- Development and cross-sectional validation of the Childhood Asthma Control Test . J Allergy Clin Immunol . 2007;119:817–825
- Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists . J Allergy Clin Immunol . 2006;117:549–556
- Global Initiative for Asthma. Global strategy for asthma management and prevention. In: National Institutes of Health. National Heart, Lung, and Blood Institute, 2008. Available at: http://www.ginasthma.com/ [Date accessed: December 20, 2008]
- . Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics . Am Rev Respir Dis . 1990;142:832–836
- . Expert panel report 3: guidelines for the diagnosis and management of asthma . Available at: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf [Date accessed: December 20, 2008]
- Airway cell and cytokine changes in early asthma deterioration after inhaled corticosteroid reduction . Clin Exp Allergy . 2007;37:1189–1198
- Development of the asthma control test: a survey for assessing asthma control . J Allergy Clin Immunol . 2004;113:59–65
- . Lung function and immunopathological changes after inhaled corticosteroid therapy in asthma . Eur Respir J . 1992;5:73–79
- . Mechanism of action of inhaled corticosteroids in bronchial asthma: a controlled study . Eur Respir J . 1994;7:421S; [Abstract]
- . Molecular mechanisms of glucocorticoid action in asthma . Pulm Pharmacol Ther . 1997;10:3–19
- . Inhaled corticosteroids in the treatment of respiratory allergy: safety vs. efficacy . J Pediatr (Rio J) . 2006;82:S198–S205
- The C-C chemokine receptors CCR4 and CCR8 identify airway T cells of allergen-challenged atopic asthmatics . J Clin Invest . 2001;107:1357–1364
- . T-helper 1-related chemokines in the exacerbation of childhood asthma . Pediatr Int . 2008;50:99–102
- . The potential role of tumour necrosis factor alpha in asthma . Clin Exp Allergy . 1993;23:247–250
- . Exhaled biomarkers . Chest . 2006;130:1541–1546
- . Exhaled nitric oxide in childhood asthma: a review . Clin Exp Allergy . 2008;38:246–259
- . Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children . Cochrane Database Syst Rev . 2007; CD002310.
- . Fluticasone and budesonide nanosuspensions for pulmonary delivery: preparation, characterization, and pharmacokinetic studies . J Pharm Sci . 2008;97:4869–4878
PII: S1875-9572(10)60007-1
doi:10.1016/S1875-9572(10)60007-1
© 2010 Taiwan Pediatric Association. Published by Elsevier Inc. All rights reserved.
